Who Supplies Cyclophosphamide to India from ARGENTINA

To import finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) into India, the following regulatory steps are mandatory:

1. Import Registration and License: Obtain an import license from the Central Drugs Standard Control Organization (CDSCO) as per the Drugs and Cosmetics Act, 1940, and associated rules. This license is essential for the legal import and sale of pharmaceutical products in India.

2. CDSCO Registration: The product must be registered with CDSCO, ensuring compliance with Indian standards for safety, efficacy, and quality.

3. Form CT-20/40/41: Depending on the product's classification, submit the appropriate form (CT-20 for new drugs, CT-40 for clinical trial imports, or CT-41 for restricted drugs) to CDSCO for approval.

4. DCGI Approval: The Drug Controller General of India (DCGI) must approve the product, confirming its compliance with Indian regulations.

5. No Objection Certificate (NOC): If the product is already marketed in another country, an NOC from the regulatory authority of that country may be required.

Timeline: The import drug registration process can take several months, depending on the completeness of the application and the regulatory workload.

For Cyclophosphamide formulations under HS Code 30049041, ensure all documentation, including manufacturing licenses, stability data, and quality control certificates, are in order to facilitate a smooth approval process.

Imported finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) must undergo stringent quality testing and batch certification to ensure compliance with Indian standards:

1. CDSCO-Approved Laboratory Testing: Samples from each batch must be tested in laboratories approved by CDSCO to verify the product's quality, safety, and efficacy.

2. Batch-Wise Requirements: Each batch imported into India requires a Certificate of Analysis (CoA) from the manufacturer, detailing the product's composition, purity, and compliance with specified standards.

3. Stability Data: Provide stability data demonstrating the product's shelf-life under Indian climatic conditions, adhering to ICH Zone IV guidelines.

4. Indian Pharmacopoeia Standards: Ensure the product meets the standards set by the Indian Pharmacopoeia, which may include specific tests for identity, purity, and strength.

5. Port Inspection: Customs drug inspectors may conduct inspections at Indian ports to verify compliance with regulatory requirements.

Non-compliance with these requirements can lead to delays, rejections, or destruction of the imported goods.

Between 2024 and 2026, India has implemented several regulatory updates affecting the import of finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041):

1. CDSCO Regulatory Updates: CDSCO has introduced stricter guidelines for the import of pharmaceutical products, emphasizing enhanced quality control measures and more rigorous testing protocols.

2. PLI Scheme Impact: The Production Linked Incentive (PLI) scheme, aimed at boosting domestic manufacturing, has led to increased scrutiny of imported formulations, potentially affecting the volume of imports.

3. Bilateral Agreements with Argentina: India and Argentina have engaged in discussions to streamline trade processes, including mutual recognition of Good Manufacturing Practices (GMP), which may facilitate smoother import procedures for Argentine pharmaceutical products.

These developments underscore the importance of staying informed about regulatory changes to ensure compliance and maintain uninterrupted trade.

India imports finished Cyclophosphamide formulations to meet the therapeutic needs of its population, particularly for cancer treatments. The demand arises due to factors such as:

1. Patented/Branded Formulations: Imported formulations may offer patented or branded products not available from domestic manufacturers.

2. Specific Dosage Forms: Certain dosage forms or strengths of Cyclophosphamide may not be produced locally, necessitating imports.

3. Domestic Capacity vs. Import Dependency: While India has a robust pharmaceutical manufacturing sector, the complexity and cost of producing certain formulations may lead to reliance on imports.

The market size for Cyclophosphamide formulations in India is substantial, driven by the prevalence of cancer and the need for effective chemotherapy agents.

The import of finished pharmaceutical formulations containing Cyclophosphamide (HS Code 30049041) into India is subject to the following customs duties:

1. Basic Customs Duty (BCD): 10% of the CIF (Cost, Insurance, and Freight) value.

2. Social Welfare Surcharge (SWS): 10% of the BCD, amounting to 1% of the CIF value.

3. Integrated Goods and Services Tax (IGST): 18% of the total value (CIF + BCD + SWS).

4. Anti-Dumping Duty: Currently, there is no anti-dumping duty imposed on Cyclophosphamide formulations from Argentina.

5. Exemption Notifications: No specific exemptions or concessional rates apply to imports from Argentina.

The total landed duty percentage is approximately 29.8% of the CIF value.

India sources finished Cyclophosphamide formulations from Argentina due to several competitive advantages:

1. Patents and Specialized Dosage Forms: Argentine manufacturers may offer patented formulations or specialized dosage forms not available from other suppliers.

2. Quality Assurance: Argentina's pharmaceutical industry adheres to international quality standards, ensuring the safety and efficacy of its products.

3. Competitive Pricing: Argentine products may be competitively priced, offering value for money compared to other suppliers.

Other major suppliers to India include China, Germany, and the United States. Argentina's share in the Indian market for Cyclophosphamide formulations is approximately 4.35%, with the United States being the largest exporter.